Jonathan D. Schoenfeld

Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy

Adrienne Luoma, Shengbao Suo, Yifan Wang et al. · Cell · 2022 · 371 citations · Full text

Life Sciences, Immunology, Oncology +16

Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial

Ravindra Uppaluri, Katie M. Campbell, Ann Marie Egloff et al. · Clinical Cancer Research · 2020 · 365 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma

Jonathan D. Schoenfeld, Glenn J. Hanna, Vickie Y. Jo et al. · JAMA Oncology · 2020 · 347 citations · Full text

Medicine, Immunology, Oncology +17

Frameshift events predict anti–PD-1/L1 response in head and neck cancer

Glenn J. Hanna, Patrick H. Lizotte, Megan E. Cavanaugh et al. · JCI Insight · 2018 · 279 citations · Full text

Medicine, Oncology, Pharmacology +17

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial

Jonathan D. Schoenfeld, Anita Giobbie‐Hurder, Srinika Ranasinghe et al. · The Lancet Oncology · 2022 · 232 citations · Full text

Medicine, Oncology, Radiation Oncology +14